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Introduction
Immunoassays are still gaining importance in the central
laboratories of large hospitals (see table 1). This trend
means that automated techniques are becoming more
desirable for immunoassays and many manufacturers are
developing new analytical systems. Therefore, it is
valuable to examine the technical and analytical require-
ments for these devices.
Very often new immunoassay systems are introduced
with a test panel based on the most commonly used tests.
In the central laboratory ofour hospital, about 70 various
immunoassays are performed. The first 10 of the most
frequently applied tests are listed on table 1. This list
most probably differs from laboratory to laboratory and
contains a very heterogenous group. Most laboratories
would not like to buy a new system which could only deal
with these tests and rather prefer analytical systems
which perform complete panels of groups which are
referred to specific disease entities such as complete
thyroid panel or hepatitis panel, instead of a mixture of
most commonly used tests (table 2).
Technical requirements
More general requirements refer to automation indepen-
dently of the type of analytical system or of the tests
performed: for example free positioning of samples,
several barcodes for sample identification, bidirectional
communication with central data processing system,
small void volume (50 btl), detection of sample exhaus-
tion, speed, reasonable size. This list is not comprehen-
sive and contains only the most common claims, because
these claims are not specific to immunoassays, they will
not be discussed in any more detail in this paper.
Among specific claims for immunoassays, 4 major claims
should be mentioned: selective multitesting, full automa-
tion, completion of panels and high throughput rate.
Since several years many laboratories have claimed
selective multitesting as it is now satisfactorily solved in
classical clinical chemistry. This need is now recognized
by industry and many companies are developing such
analytical systems for immunoassays. Selective multitest-
ing should not be confused with the term random access
which should be replaced by the term selective access ].
Table 1. Number of the 10 most often requested immunoassays
during January in the central laboratory of a 1500 bed hospital.
1988 1989 1990 1991
TSH 307 301 356 385
T4 308 284 371 247
T3 233 232 287 268
Ferritin 176 200 232 242
[32-Mikroglobulin 8 113 171 238
CEA 359 252 245 237
PSA 54 171 201 221
CA 19-9 158 121 125 151
Cortisol 126 113 97 144
Freies striol 151 148 124 138
The throughput rate ofautomated immunoassays should
be at least 100 tests (results) per hour and short
incubation times of less than one hour if the system is
designed for larger laboratories.
Analytical requirements
Principles
All immunoassays are based on the reaction ofan antigen
with a more or less specific binding protein, which in most
cases is an antibody (see figure 1). The design of this
reaction needs consideration of several other auxiliary
reactions, all of which can cause problems. This is
demonstrated in figure for a solid phase technique. This
reaction can be directly detected by turbidity measure-
ments, or indirectly detected by including a ’tracer’.
Tracers have been radioisotopes for nearly three decades.
There is now a clear trend to replace these tracers by non-
isotopes for two principal reasons: to avoid radioactivity,
and to improve the chances of automation. Several
solutions are now commercially available, which provide
sufficient analytical realibility (see table 3).
Three detection principles are presently used: absor-
bance, fluorescence and luminescence. Luminescence is
the newest solution. Although luminescence was first
described more than 300 years ago, it has been shown
only very recently by highly sensitive photomultipliers
that luminescence is a universal property of all organic
compounds that can be oxidized. This luminescence is
mostly minimal and not suitable for analytical purposes.
However, during the last decades about 100 substances
have been detected which have sufficient light emission to
be used by the commonly applied detection systems. The
most suitable substances are listed in table 3.
There is already a confusing variety oftechnologies. They
can be classified by three principles:
(1) Type of label or tracer.
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Problems: Requirements for the design of an Immunoassay
Strong Binding (Detergent, Salts)
Low Background Signal
High Binding Capacity
Long term Stability Signal
Analyte En me
Highly Specific
High Affinity
Reacting with different Epitopes
Good Titer (polyclonal) or
Efficient Producer in Mice or Bioreactor
Fast Kinetics
No Interference with Serum
Components
High Stability
Reaction Vessel
Bound/Free Separation Tool
Detection Device
Figure 1. Requirementsfor the design ofan immunoassay (provided by Dr Kawaletz, Boehringer Mannheim Corp.). The numbers represent
binding proteins (e.g. antibodies).
(2) Inclusion of a separation step (homogenous/
heterogenous test).
(3) Competitive principle or extraction-saturation.
Masseyef has proposed a three-dimensional scheme [2],
which, however, is only valid for a rough orientation.
Acceptability criteria
Precision
In classical clinical chemistry, many procedures have a
linear relationship between standard deviation and
analyte concentration. With most immunoassays the
Table 2. Immunoassay panels.
1. Thyroid: T4, T3, T-uptake, TSH, FT4
2. Anemia: B12, folate, ferritin
3. Fertility: hCG, FSH, LH, prolactin, estradiol, pro-
gesterone, testosterone
4. Pregnancy: hCG, AFP, HPL, estriol
5. Other hormones: cortisol, STH, PTH
6. Hepatitis: HBsAg, HBeAg, anti=HBs, anti-HBe, anti-
HBc, anti-HBcIgM, anti-HAV, anti-
HAVIgM, anti-HCV
7. Other infectious diseases: chlamydia, HIV
8. Tumour markers: CEA, AFP, PSA, Ca 19-9, Ca 12-5
precision profile is more or less like a parabel (figure 2).
Therefore, precision limits must be defined for various
intervals of the whole analytical range. This will be
demonstrated with thyrotropin (TSH) as an example
(figure 3): the reference range covers one order of
magnitude (0"3-0"4 mU/1), the range below 0" indicates
hyperthyroidism; the range above 10"0, hypothyroidism
with high certainty. Which precision is required in the
three parts of the analytical range? Another question is:
what interval between A and B should be chosen, or can
be omitted?
It is now generally accepted that analytical imprecision
goals can be based on the biological variability. However,
several proposals have been issued concerning the
acceptable fraction of the analytical variability (table 4).
According to the first proposal in table 4, the analytical
imprecision for TSH should be equal or smaller than 8"
[3]. This goal is usually considered to be independent of
sex and age, and to be constant in the reference range.
When the ’ultrasensitive TSH’ tests were developed, the
discussion on analytical goals in the lower part of the
analytical range was renewed.
A special case is the imprecision of the blank which is
used as a measure of the detection limit. A survey of
definitions has recently been published [5]. It is generally
considered to be the minimally detectable quantity.
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Table 3. Non-isotopic immunoassays.
Method Label
Analytical system
(distributor)
Absorbance
ELISA
EIA
EMIT
EASIA
Fluorescence
FPIA (polarization)
MEIA (microbeads)
TRFIA (time resolved)
FEIA (radial partition)
FETI
Luminescence
LEIA (enhanced)
CLIA
SPALT (solid phase)
ILMA
ABTS/POD
phenolphtalein/AP
NADH/G6PDH
TMB/POD
fluorescein
umbelliferon/AP
Eu (13NTA)
umbelliferon/AP
fluorescein
luminol/POD
acridiniumester
acridinimnester
ABEI/AP, POD
ES 600 (BMC)
SR (Serono)
Spektrometer (Syva)
Vmax (Medgenix)
TDX (Abbott)
IMX (Abbott)
Delfia (Pharmacia)
Stratus (Baxter)
Advance (Syva)
Amerlite (Amersham)
Magic-Lite (Ciba Corning)
Berilux (Behring)
Liamat (Byk-Sangtec)
cv %
#1 c
00"- 10 20 30 40
TSH concentration,uu/l
Figure 2. Typical relationship between the coefficient of variation
and the analyte concentration ofan immunoassay.
Again, several proposals exist for the measurement of
imprecision of the blank (table 5). Ekins has suggested
calculating imprecision from duplicates of patients’
samples taken from the whole analytical range, to
calculate standard deviations from several intervals ofthe
analytical range and then to extrapolate to the theoretical
standard deviation for an analyte free sample, that means
to a real blank value [4]; Ekins’ procedure may imitate
’the real sample conditions’ more realistic than aqueous
standard solutions with an artificial matrix [5].
Ifthe detection limit is defined, and ifit is below the lower
end of the reference range, the following claims can be
recommended for the determination of the TSH activity:
(1) 1% criterion for detection limit (DE 0"05 U/l).
(2) CVA at lower limit of the reference range --<8%.
TSH
overlapping
range
reference range overlapping
range
hyperthyroid
(over 95 %)
euthyroid
(95 %)
hypothyroid
(I00 %)
0,2 4,6
(I00 %)
Figure 3. Various sections of the analytical rangefor the determination of thyrotropin concentration in human serum.
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Table 4. Acceptable limits of imprecision, CV coefficient of
variation, A analytical, B biological variability.
1. Cotlove, Harris, Fraser [7-9]
(intraindividual variability)
CVA --< 1/2 CVu
2. Stamm [6]
(interindividual variability)
CVA --< 1/3 CVu 1/12 reference range
3. NCCLS [10]
(intraindividual variability)
CVA 1/4 CVs
(3) The calibrator with the lowest concentration should
be between DL and the lower limit of the reference
range.
Analogue considerations
immunoassays.
can be made for other
Accuracy
The accuracy of many immunoassays, especially for
hormone analyses, has two major problems which still
require substantial international effort: the calibration of
the assays and the specificity of the antibodies.
Standardization of calibrators: In the case of peptides and
protein antigens, calibration of the various procedures
depend on the purity and definition of the calibrators. In
most cases it is not yet possible to produce calibrators
with the purity required at a reasonable cost. Therefore,
the only possible way for this moment, is to trace back
calibration to calibrators with internationally accepted
concensus values. Such international reference materials
are usually produced by or under the auspices ofWHO,
or similar organizations.
Specificity of antibodies: Much progress has been achieved
by the introduction of monoclonal antibodies. A next
important step should be epitope mapping to define
antibody specificity and comparison with bioassays to
prove the biorelevance of the epitope detected by the
monoclonal antibodies. The specificity of antibodies for
particular antigen epitopes is still relatively unknown.
Table 5. Proceduresfor determining the detection limit [5].
1.1
1.2
2.
2.1
2.2
Blank sample methods
One series
Multiple blank duplic.ates
Precision profile methods
Using calibrators
Using unknown samples
In the case ofproteins, the antigen characteristics depend
on the physical-chemical structure relationship. That
means: the availability of antigen determinants are
variable. Denaturation and fragmentation can lead to
loss of antigen determinants or even to new determinants
which are called ’additive epitopes’.
Acceptability criteriafor inaccuracy: Criteria for the accepta-
bility of inaccuracy are usually based on imprecision
criteria, for example [5]:
X XR
XR
100 3 CVA
XR reference method value, X value measured and
CVA coefficient ofvariation (analytical goal calculated
from biological variability).
For TSH this would mean that inaccuracy should be less
than 24%. With a two standard deviation range it would
be 16%.
Conclusion
In conclusion, analytical performance criteria should be
established for each test, as demonstrated for TSH, and
these goals must also be reached by automated systems.
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